Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease

Figure 2 Receiver operating curves of type IV collagen, PIIIP, HA and YKL-40 for predicting stages greater than F3. The predictive ability of serum HA exceeded that of another serum markers (AUC = 0.854). The ability to predict cirrhosis (F4) from chronic hepatitis C (F0-3) was AUC = 0.795 for YKL-40 and AUC = 0.790 for PIIIP.